» Articles » PMID: 27270311

Direct Contact with Perivascular Tumor Cells Enhances Integrin αvβ3 Signaling and Migration of Endothelial Cells

Overview
Journal Oncotarget
Specialty Oncology
Date 2016 Jun 9
PMID 27270311
Citations 25
Authors
Affiliations
Soon will be listed here.
Abstract

The secretion of soluble pro-angiogenic factors by tumor cells and stromal cells in the perivascular niche promotes the aggressive angiogenesis that is typical of glioblastoma (GBM). Here, we show that angiogenesis also can be promoted by a direct interaction between brain tumor cells, including tumor cells with cancer stem-like properties (CSCs), and endothelial cells (ECs). As shown in vitro, this direct interaction is mediated by binding of integrin αvβ3 expressed on ECs to the RGD-peptide in L1CAM expressed on CSCs. It promotes both EC network formation and enhances directed migration toward basic fibroblast growth factor. Activation of αvβ3 and bone marrow tyrosine kinase on chromosome X (BMX) is required for migration stimulated by direct binding but not for migration stimulated by soluble factors. RGD-peptide treatment of mice with established intracerebral GBM xenografts significantly reduced the percentage of Sox2-positive tumor cells and CSCs in close proximity to ECs, decreased integrin αvβ3 and BMX activation and p130CAS phosphorylation in the ECs, and reduced the vessel surface area. These results reveal a previously unrecognized aspect of the regulation of angiogenesis in GBM that can impact therapeutic anti-angiogenic targeting.

Citing Articles

Endothelial-secreted Endocan activates PDGFRA and regulates vascularity and spatial phenotype in glioblastoma.

Bastola S, Pavlyukov M, Sharma N, Ghochani Y, Nakano M, Muthukrishnan S Nat Commun. 2025; 16(1):471.

PMID: 39773984 PMC: 11707362. DOI: 10.1038/s41467-024-55487-1.


Enhancing Tumor Targeted Therapy: The Role of iRGD Peptide in Advanced Drug Delivery Systems.

Nikitovic D, Kukovyakina E, Berdiaki A, Tzanakakis A, Luss A, Vlaskina E Cancers (Basel). 2024; 16(22).

PMID: 39594723 PMC: 11592346. DOI: 10.3390/cancers16223768.


Extracellular vesicles in non-small cell lung cancer stemness and clinical applications.

Pandya P, Al-Qasrawi D, Klinge S, Justilien V Front Immunol. 2024; 15:1369356.

PMID: 38765006 PMC: 11099288. DOI: 10.3389/fimmu.2024.1369356.


Thy-1 (CD90)-regulated cell adhesion and migration of mesenchymal cells: insights into adhesomes, mechanical forces, and signaling pathways.

Valdivia A, Avalos A, Leyton L Front Cell Dev Biol. 2023; 11:1221306.

PMID: 38099295 PMC: 10720913. DOI: 10.3389/fcell.2023.1221306.


Exploring the dynamic interplay between cancer stem cells and the tumor microenvironment: implications for novel therapeutic strategies.

Li Y, Fang Y, Lyu Z, Zhu Y, Yang L J Transl Med. 2023; 21(1):686.

PMID: 37784157 PMC: 10546755. DOI: 10.1186/s12967-023-04575-9.


References
1.
Oleszewski M, Beer S, Katich S, Geiger C, Zeller Y, Rauch U . Integrin and neurocan binding to L1 involves distinct Ig domains. J Biol Chem. 1999; 274(35):24602-10. DOI: 10.1074/jbc.274.35.24602. View

2.
Chatterjee S, Matsumura A, Schradermeier J, Gillespie G . Human malignant glioma therapy using anti-alpha(v)beta3 integrin agents. J Neurooncol. 2000; 46(2):135-44. DOI: 10.1023/a:1006444300504. View

3.
Holopainen T, Lopez-Alpuche V, Zheng W, Heljasvaara R, Jones D, He Y . Deletion of the endothelial Bmx tyrosine kinase decreases tumor angiogenesis and growth. Cancer Res. 2012; 72(14):3512-21. DOI: 10.1158/0008-5472.CAN-11-1070. View

4.
Nikonova A, Gaponova A, Kudinov A, Golemis E . CAS proteins in health and disease: an update. IUBMB Life. 2014; 66(6):387-95. PMC: 4111207. DOI: 10.1002/iub.1282. View

5.
Bao S, Wu Q, Li Z, Sathornsumetee S, Wang H, McLendon R . Targeting cancer stem cells through L1CAM suppresses glioma growth. Cancer Res. 2008; 68(15):6043-8. PMC: 2739001. DOI: 10.1158/0008-5472.CAN-08-1079. View